Table 1.

Ongoing trials evaluating combination PD-L1 and CTLA-4 blockade in HNSCC.

Trial	Phase	Cohort	Drugs	Trial code
CheckMate 356	I/II	EBV positive nasopharyngeal cancers, HPV positive HNSCC	Ipilimumab and Nivolumab	U111-1166-0687
CheckMate 714	II	Recurrent or metastatic HNSCC	Ipilimumab and Nivolumab vs. Nivolumab and Placebo	NCT02823574
CheckMate 651	III	First line treatment for HNSCC	Ipilumumab and Nivolumab vs. Cetuximab with platinum and flurouracil	NCT02741570
KESTERAL	III	Recurrent or metastatic HNSCC	Durvalumab and Tremelimumab vs. Durvalumab monotherapy	NCT02551159

Durvalumab, IgG1 antibody to PD-L1; EBV, Epstein-Barr Virus; Ipilimumab, IgG1 antibody to CTLA-4; Tremelimumab, IgG2 antibody to CTLA-4.